The Future of Lymphoma Treatment? Personalized Care

For many cancer patients, chemotherapy can be worse than cancer itself. A patient may respond to one drug but not another, or the tumor may mutate and stop responding to the drug, resulting in months of wasted time, ineffective treatment and toxic side effects.


A great blogger on Lymphoma, Lymphoma Bob (http://lymphobob.blogspot.com) explains it this way: They altered a chemotherapy drug so that it could be traced with a PET scan, creating a "tag" that would show up on the PET. They gave the drug to mice with leukemia and lymphoma, then gave them a PET. The PET allowed them to see the tagged drug being absorbed by the tumor.



The researchers think that this will work on humans, too; they'll be able to give a small amount of a tagged drug to cancer patients and then see on a PET whether or not it was being absorbed by the tumor. If it isn't being absorbed, they know the chemo won't work, and they'll try a different treatment. That's one kind of "personalization" that we can look forward to in the near future.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap